Thursday, March 21, 2013
This week in
Publication and contact
Controlled Fab-arm exchange
(cFAE) approach to develop bispecific antibodies for therapeutic use
In vitro and mouse studies identified a method to develop
bispecific antibodies as therapeutics. The cFAE method involved expressing
matched mutant methyl domains in two IgG1
antibodies and combining the antibodies with a weak reducing agent to
preserve the heavy-chain and light-chain pairings. Bispecific antibodies were
designed including those that target both CD20
as well as those that target HER2 and CD3.
In cancer cells and in mice xenograft models for gastric carcinoma, the HER2-
and CD3-targeting antibody decreased cancer cell survival compared with a
control antibody. Next steps include developing bispecific antibody
Published online March 21, 2013
Patent applications filed;
licensed to Novartis
AG, Janssen Pharmaceuticals N.V., Kyowa
Hakko Kirin Co. Ltd. and an undisclosed company for
specific programs; available for licensing
Labrijn, A.F. et al.
Proc. Natl. Acad. Sci. USA; published online March 11, 2013;
Contact: Paul W.H.I. Parren, Genmab A/S, Brooklyn Park,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]